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Abstract
Prostate cancer susceptibility has previously been associated with truncating germline variants in the gene TP53AIP1 (tumor
protein p53 regulated apoptosis inducing protein 1). For two apparently recurrent mutations (p.Q22fs and p.S32X) a
remarkable OR of 5.1 was reported for prostate cancer risk. Since these findings have not been validated so far, we
genotyped p.Q22fs and p.S32X in two German series with a total of 1,207 prostate cancer cases and 1,495 controls. The
truncating variants were not significantly associated with prostate cancer in none of the two cohorts, nor in the combined
analysis [odds ratio (OR)=1.16; 95% confidence interval (CI 95%)=0.62–2.15; p=0.66]. Carriers showed no significant
differences in family history of prostate cancer, age at diagnosis, Gleason score or PSA at diagnosis when compared to non-
carrier prostate cancer cases. The large sample size of the combined cohort rejects a high-risk effect greater than 2.2 and
indicates a limited role of TP53AIP1 in prostate cancer predisposition.
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Introduction
Prostate cancer (PrCa) is the most frequent tumor and the third
leading cause of cancer related death in men in the western
industrial world [1]. In the etiology of PrCa a considerable degree
of heritability is assumed to be involved [2]. To date, more than 30
moderately risk-associated single nucleotide polymorphisms have
been identified in genome wide association studies, which explain
a minor fraction of heritability [3]. In contrast, high risk genes
which could be responsible for the majority of the observed
familial clustering are still unknown.
There is growing evidence that genes involved in DNA damage
response play a predisposing role for PrCa [4]. This includes DNA
repair processes as well related mechanisms like apoptotic
pathways. TP53AIP1 (tumor protein p53 regulated apoptosis
inducing protein 1) plays a key role in the tumor suppressor p53
dependent apoptotic signaling. TP53AIP1 is localized in the
mitochondrial membrane and mediates apoptosis through cyto-
chrome c release [5]. The expression of TP53AIP1 is triggered
upon severe damage by phosphorylation of p53 at Ser46 [6].
TP53AIP1 was found to be mutated in PrCa tissue in a recent
study [7]. The two identified truncating mutations p.Q22fs and
p.S32X turned out to be recurrent germ-line variants and were
strongly associated with PrCa risk (OR of 5.1), thus suggesting
TP53AIP1 as a promising susceptibility gene. In the present study
we have evaluated the risk effect of these two TP53AIP1 mutations
in two independent German PrCa cohorts.
Results
Both truncation variants were observed in our cohorts. While
the frameshift allele p.Q22fs was present in 1.8% cases and 1.6%
controls, the nonsense mutation p.S32X appeared to be
comparably rare (0.1% carriers in both cases and controls).
Overall, p.Q22fs and p.S32X were not associated with prostate
cancer risk, neither in the combined series of Ulm and Hannover,
nor in each individual sample (Table 1). No evidence against
homogeneity was observed among the Ulm and Hannover series
(p=0.39). Accumulation in familial prostate cancer cases could
indicate a high risk effect mediated by the variants. This
hypothesis was tested in the Ulm series, which contained a
collection of PrCa cases with positive family history. However no
enrichment of the mutations was observed in familial cases (6 out
of 377 (1.6%)) when compared to sporadic cases (7 out of 325
(2.1%)). Finally, clinical subgroups of cases were defined in order
to elucidate trends towards aggressive tumor forms. The mutation
carriers showed no significant difference from non-carriers in
severity of prostate cancer, as determined by age of onset, Gleason
score, or PSA level prior treatment (Table 2).
Discussion
TP53AIP1 has been suggested as a PrCa susceptibility gene,
since two recurrent germline mutations (p.Q22fs and p.S32X)
were found considerably overrepresented among PrCa patients
within a previous case-control study [7]. For the purpose of
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approximately 1,200 prostate cancer cases and 1,500 controls,
but we failed to replicate an association of these variants with PrCa
risk.
The discrepancies between the present and the initial study
could be explained by several factors, including variable ethnic
backgrounds, different sample sizes and diverging inclusion
criteria. Population-specific differences have become evident in
the case of p.S32X, as this variant has been found rarely in
German probands, and thus could not be evaluated for disease
association. The most obvious difference between the study
samples is the frequency of variant p.Q22fs, which appeared
much lower in the control group of Wang and colleagues as
compared to our controls (0.3% versus 1.6%, respectively).
Noteworthy, Wang et al. have recruited healthy, age matched
controls, which could be more powerful to detect associations with
prostate cancer risk, despite of their 4.5-fold smaller sample size. In
contrast, the unselected controls for our comparisons may contain
misclassified prostate cancer cases at population prevalence levels,
so that true disease effects would appear slightly understated.
However, power estimations suggest that the loss of power by
choosing population controls instead of ‘‘super controls’’ would be
small for a disease with an about 10% incidence rate, and that this
loss can be efficiently compensated for by modest increases in
sample size [8]. The fact that we observed virtually equal carrier
frequencies in both cases and controls strongly argues against an
association of p.Q22fs with PrCa. Based on the sample sizes
enrolled here, a resulting interval of confidence rules out any risk
effect greater than 2.2 for p.Q22fs and p.S32X.
In subgroup analyses we have considered predisposing roles of
TP53AIP1 mutations particularly for familial and for aggressive
PrCa. No accumulation of p.Q22fs and p.S32X was observed in
familial cases, rejecting the hypothesis of a high penetrance of
these mutations. Finally, the lack of genotype/phenotype corre-
lation with respect to clinical parameters argues against suscep-
tibility to more severe forms of PrCa for the mutation carriers.
Aside from truncating mutations examined in the present study,
a missense substitution (p.A7V) in TP53AIP1 has previously been
studied in the Hannover series. Similarly, the p.A7V variant also
had not shown an increased frequency in prostate cancer cases [9].
We conclude that there is little support at present to regard
TP53AIP1 as a prostate cancer susceptibility gene.
Materials and Methods
Probands
Two series of cases and controls were pooled for this study,
recruited at the Universities of Ulm and Hannover, Germany. All
probands were of Caucasian origin. The study was approved by
the Institution Review Board of Ulm (Ethikkommission der
Universita ¨t Ulm - vote number 87/97) and the Institution Review
Board of Hannover (Ethikkommission der Medizinischen
Hochschule Hannover - vote number 3894/05). Written informed
consent, according to the Institution Review Boards, was obtained.
From the Prostate Cancer Genetics Project of Ulm a total
number of 377 familial and 325 sporadic cases were included. The
recruitment scheme of these patients is described elsewhere [10].
The median age of diagnosis was 63 years (range 40–84 years) and
Table 1. Genotype specific odds ratio (OR), exact 95% confidence interval (CI 95%) and p-values of truncating TP53AIP1 variants in
case control comparisons.
genotype, n (%)
n p.Q22fs het
a p.S32X het
a p.Q22fs or p.S32X het
a
normal
(wild-type) OR (CI 95%) p-value
all controls 1495 24 (1.6%) 1 (0.1%) 25 (1.7%) 1470 (98.3%) ref.
all cases 1207 22 (1.8%) 1 (0.1%) 23 (1.9%) 1184 (98.1%) 1.16 (0.62–2.15) 0.66
controls Ulm 995 18 (1.8%) 1 (0.1%) 19 (1.9%) 976 (98.1%) ref.
cases Ulm
b 702 13 (1.9%) 0 (0%) 13 (1.9%) 689 (98.1%) 0.97 (0.44–2.08) 1.00
controls Hannover 500 6 (1.2%) 0 (0%) 6 (1.2%) 494 (98.8%) ref.
cases Hannover 505 9 (1.8%) 1 (0.2%) 10 (2.0%) 495 (98.0%) 1.66 (0.54–5.61) 0.45
a: heterozygous.
b: including 377 familial and 325 sporadic prostate cancer patients.
doi:10.1371/journal.pone.0034128.t001
Table 2. Comparison of age at diagnosis, Gleason Score and PSA at diagnosis between carriers of the truncating TP53AIP1 variants
and non-carriers.
p.Q22fs or p.S32X het
a normal (wild-type)
n
b mean (SD) n
b mean (SD) p-value
age at diagnosis 23 63.5 (66.7) 1174 64.4 (66.7) 0.53
Gleason Score 20 5.9 (61.1) 1009 6.1 (61.1) 0.42
PSA at diagnosis [ng/mL] 21 12.2 (610.3) 1087 13.6 (653.0) 0.91
a: heterozygous.
b: probands with available information for specified parameter.
doi:10.1371/journal.pone.0034128.t002
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tests 995 population controls from Ulm were used.
The Hannover prostate cancer study (HaPCS) consists of a
hospital-based series of 505 unselected patients with PrCa who
were treated with brachytherapy between October 2000 and
September 2007 at Hannover Medical School [9]. All patients had
biopsy-proven adenocarcinoma of the prostate. Indication for
permanent brachytherapy was clinically localized low risk early
PrCa (cT2a or less with a PSA serum level ,10 ng/ml and a
Gleason score ,7). The median age at diagnosis was 67 years
(range 42–82 years). For comparison, 504 genomic DNA samples
were collected from adult male blood donors at Hannover Medical
School between 2006 and 2007.
Genotyping
Genomic DNA, extracted from peripheral blood lymphocytes,
served as template for genotyping. The Ulm cohort was typed for
p.Q22fs with the high resolution melting (HRM) method. In brief:
PCR was performed with AmpliTaq Gold Mastermix (Applied
Biosystems, Foster City, USA). After PCR amplification 1.0 mL
EVA-Green (Biotium, Hayward, USA) was added to each sample
and the dissociation curve was measured on a 96-well 7900HT
Fast Real-Time PCR System (Applied Biosystems, Foster City,
USA). HRM data was analysed with the High Resolution Melt
software v1.1 (Applied Biosystems, Foster City, USA). The S32X
variant was typed using a Custom SNP Genotyping Assay
(Applied Biosystems, Foster City, USA) along with TaqMan
Genotyping Mastermix (Applied Biosystems, Foster City, USA) in
a total volume of 5 mL on a 384-well 7900HT Fast Real-Time
PCR System (Applied Biosystems, Foster City, USA). For positive
controls we used plasmids corresponding to the truncating allele
p.Q22fs or p.S32X respectively and the normal allele. Normal
allele and mutant plasmids were mixed 1:1 in order to mimic
heterozygous genotypes. Genotyping of the Hannover series was
performed with restriction fragment length polymorphism analyses
usingBglIforp.Q22fsand BfaIforp.S32X,afterPCRamplification.
Primer and probe sequences, as well PCR conditions will be given
on request. Samples that were identified to carry the p.Q22fs or
p.S32X variant by any of the utilized screening methods were
verified by Sanger sequencing.
Statistical analyses
Associations between genotypes and disease status were assessed
with SAS 9.2 (SAS, Cary, USA). Odds ratios and exact 95%
confidence intervals are given, along with p-values by Fisher’s
exact test. For the combined analyses homogeneity of the odds
ratios where checked by Breslow-Day test and the combined odds
ratio was calculated with Mantel-Haenszel test. The unpaired T-
test was used for comparison of clinical parameters in the mutation
carriers and non-carriers and was calculated with StatView 5.01
(SAS, Cary, USA).
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